Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial
Patients in the dexmedetomidine arm had a significantly lower response to phenylephrine at all study times including baseline, which might have contributed to higher early mortality in the dexmedetomidine arm and preclude to conclude on dexmedetomidine efficacy in refractory septic shock. However, heart rate was not decreased in the dexmedetomidine arm.
Authors
- Amélie Cransac (ORCID: https://orcid.org/0000-0003-1836-2619)
- Abderrahmane Bourredjem (ORCID: https://orcid.org/0000-0003-0908-053X)
- Marine Jacquier
- Auguste Dargent (ORCID: https://orcid.org/0000-0003-1784-1212)
- Julio Badié
- Isabelle Fournel (ORCID: https://orcid.org/0000-0002-3061-9715)
- Luc Quintin (ORCID: https://orcid.org/0000-0003-0714-0500)
- Jean‐Pierre Quenot (ORCID: https://orcid.org/0000-0003-2351-682X)
- Laurent Argaud
- Julien Bohé
- Bruno Lévy
Institutions
- Inserm (FR)
- Université de Bourgogne (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hospices Civils de Lyon (FR)
- VetAgro Sup (FR)
- CHU Dijon Bourgogne (FR)
- Hôpital d'instruction des Armées Desgenettes (FR)
- L'Hôpital Nord Franche-Comté (FR)
- Centre de recherche Translationnelle en Médecine moléculaire (FR)
- Institut des Vaisseaux et du Sang (FR)
Publication Details
- Journal
- Critical Care Medicine
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1097/ccm.0000000000006608
- Citations
- 11
- Primary Topic
- Intensive Care Unit Cognitive Disorders
- Type
- article
- Field-Weighted Citation Impact
- 17.00